|
No. of patients
|
1463
|
2339
|
3020
|
3526
|
3722
|
5879
|
|
Age, years
|
12.3 ± 3.2
|
12.6 ± 3.3
|
12.7 ± 3.4
|
12.6 ± 3.3
|
13.7 ± 2.5
|
13.1 ± 3.3
|
|
BMI, kg/m2
|
─
|
19.4 ± 3.8
|
19.4 ± 3.9
|
19.4 ± 4.8
|
19.7 ± 2.8
|
19.1 ± 3.2
|
|
Female, no. (%)
|
898 (61.4)
|
1464 (62.4)
|
1901 (62.9)
|
2246 (63.7)
|
2374 (63.8)
|
3844 (65.4)
|
|
Disease duration, years
|
4.9 ± 3.6
|
5.5 ± 3.3
|
5.3 ± 3.5
|
5.1 ± 3.3
|
5.5 ± 3.6
|
5.9 ± 4.0
|
|
Age at disease onset, years
|
7.4 ± 4.1
|
7.7 ± 4.2
|
7.7 ± 4.3
|
7.8 ± 4.2
|
8.5 ± 4.2
|
7.9 ± 4.4
|
|
JIA category, no. (%)
|
|
RF-positive polyarthritis
|
51 (3.5)
|
59 (2.5)
|
65 (2.2)
|
99 (2.8)
|
114 (3.1)
|
145 (2.5)
|
|
RF-negative polyarthritis
|
206 (14.1)
|
9 (12.3)
|
461 (15.3)
|
495 (14.0)
|
645 (17.3)
|
1084 (18.4)
|
|
Systemic JIA
|
105 (7.2)
|
127 (5.4)
|
150 (5.0)
|
164 (4.7)
|
128 (3.4)
|
264 (4.5)
|
|
Persistent oligoarthritis
|
526 (36.0)
|
943 (40.2)
|
1238 (41.0)
|
1637 (46.4)
|
1479 (39.7)
|
2165 (36.9)
|
|
Extended oligoarthritis
|
140 (9.6)
|
157 (6.7)
|
180 (6.0)
|
225 (6.4)
|
349 (9.4)
|
652 (11.1)
|
|
Psoriatic arthritis
|
133 (9.1)
|
254 (10.8)
|
275 (9.1)
|
234 (6.6)
|
225 (6.0)
|
342 (5.8)
|
|
Enthesitis-related arthritis
|
196 (13.4)
|
400 (17.0)
|
528 (17.5)
|
570 (16.2)
|
664 (17.8)
|
1052 (17.9)
|
|
Unclassified JIA
|
106 (7.2)
|
110 (4.7)
|
123 (4.0)
|
102 (2.9)
|
118 (3.2)
|
175 (2.9)
|
|
cJADAS-10
|
5.8 ± 5.5
|
4.3 ± 4.7
|
4.3 ± 4.8
|
4.0 ± 4.6
|
4.0 ± 4.7
|
4.0 ± 4.7
|
|
PGA scoreφ
|
1.7 ± 1.7
|
1.3 ± 1.7
|
1.4 ± 1.7
|
1.3 ± 1.7
|
1.4 ± 1.8
|
1.2 ± 1.8
|
|
Inactive disease*, no. (%)
|
429 (30.0)
|
952 (41.4)
|
1229 (41.3)
|
1444 (42.6)
|
1423 (39.8)
|
3130 (54.6)
|
|
No. of joints with active disease
|
3.2 ± 5.7
|
1.6 ± 3.4
|
1.6 ± 3.6
|
1.5 ± 3.3
|
1.3 ± 3.2
|
1.1 ± 2.9
|
|
ESR, mm/h
|
10.7 ± 15.1
|
11.7 ± 12.5
|
12.6 ± 14.6
|
11.7 ± 12.6
|
10.1 ± 10.7
|
11.2 ± 12.8
|
|
C-HAQ total score
|
0.3 ± 0.5
|
0.2 ± 0.4
|
0.2 ± 0.4
|
0.2 ± 0.4
|
0.2 ± 0.4
|
0.2 ± 0.4
|
|
No functional limitations†, no. (%)
|
738 (51.3)
|
1300 (55.8)
|
1717 (58.8)
|
2151 (61.4)
|
2280 (61.8)
|
3465 (59.9)
|
|
Patient-reported well-beingφ
|
1.8 ± 2.1
|
1.7 ± 2.0
|
1.7 ± 2.0
|
1.6 ± 2.0
|
1.6 ± 2.1
|
1.8 ± 2.2
|
|
Patient-reported painφ
|
1.6 ± 2.3
|
1.6 ± 2.2
|
1.6 ± 2.2
|
1.6 ± 2.3
|
1.7 ± 2.5
|
1.8 ± 2.5
|
|
Patient-reported fatigueφ
|
─
|
─
|
─
|
─
|
1.5 ± 2.5
|
1.5 ± 2.5
|
|
Patient-reported copingφ
|
1.6 ± 0.9
|
1.6 ± 0.9
|
1.4 ± 2.1
|
1.4 ± 2.0
|
1.3 ± 2.1
|
1.4 ± 2.1
|
|
Treatment in past 12 months, no. (%)
|
|
No systemic GCs
|
1103 (78.8)
|
1768 (81.3)
|
2323 (85.2)
|
2535 (88.5)
|
2683 (89.4)
|
4519 (92.4)
|
|
Low-dose GCs (< 0.2 mg/kg)
|
244 (17.4)
|
336 (15.4)
|
343 (12.6)
|
246 (8.6)
|
258 (8.6)
|
236 (4.8)
|
|
Combination of high-dose GCs/
|
|
pulse therapy
|
10 (0.7)
|
11 (0.5)
|
14 (0.5)
|
16 (0.5)
|
19 (0.5)
|
29 (0.5)
|
|
Intra-articular GCs
|
255 (18.2)
|
195 (9.0)
|
299 (11.0)
|
317 (11.1)
|
261 (8.7)
|
434 (8.9)
|
|
Any conventional synthetic DMARD
|
674 (48.9)
|
1013 (48.6)
|
1496 (56.0)
|
1672 (54.7)
|
1861 (58.0)
|
1828 (30.7)
|
|
Any biologic DMARD
|
11 (0.8)
|
114 (11.3)
|
295 (9.8)
|
432 (14.1)
|
650 (20.6)
|
1140 (22.3)
|
|
Regular exercise in leisure time (patients aged ≥13)‡, no. (%)
|
─
|
─
|
2174 (72.9)
|
2677 (77.1)
|
3029 (82.9)
|
2409 (79.1)
|
|
Physical therapies, no. (%)
|
|
Physiotherapy
|
972 (67.9)
|
1299 (56.8)
|
1645 (55.9)
|
1714 (50.4)
|
1844 (51.0)
|
2830 (49.9)
|
|
Kinetotherapeutic bath
|
132 (9.2)
|
110 (4.8)
|
130 (4.4)
|
123 (3.6)
|
96 (2.7)
|
147 (2.6)
|
|
Occupational therapy
|
119 (8.3)
|
200 (8.7)
|
316 (10.7)
|
318 (9.3)
|
381 (10.5)
|
567 (10.0)
|
|
No physical therapy
|
401 (28.0)
|
903 (39.5)
|
1177 (40.0)
|
1557 (45.7)
|
1679 (46.5)
|
2687 (47.4)
|
